The primary objectives of this clinical trial performed with Vyleesi (Bremelanotide Injection) are: * to evaluate if Bremelanotide (BMT) is secreted in breast milk of lactating women treated with a single dose of BMT 1.75 mg SC. * to measure the concentration and characterize the pharmacokinetics of BMT secreted in breast milk of lactating women treated with a single dose of BMT 1.75 mg SC. This open-label, pharmacokinetic (PK) study will be performed in 10 healthy lactating female subjects between 10 days and 6 months post-partum (inclusive). The maximum duration of subject participation in the study will be approximately 29 days, consisting of 3-week Screening period, a 1 day treatment period, and up to a 7 day follow-up period.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Levels of Bremelanotide (BMT) in Breast Milk Over 24h After Administration of Vyleesi
Timeframe: 24 hours
Area under the curve from time 0 to end of dosing interval (AUCtau) for BMT in Breast Milk
Timeframe: 24 hours
Maximum observed concentration (Cmax) of BMT in breast milk
Timeframe: 24 hours
Time to reach Cmax of BMT in breast milk (Tmax)
Timeframe: 24 hours
Terminal half-life of BMT in breast milk (t1/2)
Timeframe: 24 hours